Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
143 tokens/sec
GPT-4o
7 tokens/sec
Gemini 2.5 Pro Pro
46 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Sequential Re-estimation Learning of Optimal Individualized Treatment Rules Among Ordinal Treatments with Application to Recommended Intervals Between Blood Donations (2302.11638v1)

Published 22 Feb 2023 in stat.ME and stat.AP

Abstract: Personalized medicine has gained much popularity recently as a way of providing better healthcare by tailoring treatments to suit individuals. Our research, motivated by the UK INTERVAL blood donation trial, focuses on estimating the optimal individualized treatment rule (ITR) in the ordinal treatment-arms setting. Restrictions on minimum lengths between whole blood donations exist to safeguard donor health and quality of blood received. However, the evidence-base for these limits is lacking. Moreover, in England, the blood service is interested in making blood donation both safe and sustainable by integrating multi-marker data from INTERVAL and developing personalized donation strategies. As the three inter-donation interval options in INTERVAL have clear orderings, we propose a sequential re-estimation learning method that effectively incorporates "treatment" orderings when identifying optimal ITRs. Furthermore, we incorporate variable selection into our method for both linear and nonlinear decision rules to handle situations with (noise) covariates irrelevant for decision-making. Simulations demonstrate its superior performance over existing methods that assume multiple nominal treatments by achieving smaller misclassification rates and larger value functions. Application to a much-in-demand donor subgroup shows that the estimated optimal ITR achieves both the highest utilities and largest proportions of donors assigned to the safest inter-donation interval option in INTERVAL.

Summary

We haven't generated a summary for this paper yet.